These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35645881)

  • 1. Study of CEO Narcissism and Corporate R&D Investment.
    Wang L; Li H; Mu Y
    Front Psychol; 2022; 13():888618. PubMed ID: 35645881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How does CEO narcissism affect enterprise ambidextrous technological innovation? The mediating role of corporate social responsibility.
    Wang Z; Hu X; Yu F
    PLoS One; 2023; 18(1):e0280758. PubMed ID: 36662757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderating Effect of Chief Executive Officer Narcissism in the Relationship Between Corporate Social Responsibility and Green Technology Innovation.
    Yang H; Shi X; Wang S
    Front Psychol; 2021; 12():717491. PubMed ID: 34744876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships Among CEO Narcissism, Debt Financing and Firm Innovation Performance: Emotion Recognition Using Advanced Artificial Intelligence.
    Zhang L; Liang B; Bi D; Zhou Y; Yu X
    Front Psychol; 2021; 12():734777. PubMed ID: 34589031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEO Overconfidence, Corporate Governance, and R&D Smoothing in Technology-Based Entrepreneurial Firms.
    Huang Y; Wang X; Li Y; Yu X
    Front Psychol; 2022; 13():944117. PubMed ID: 35910989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Narcissistic CEOs on Corporate Social Responsibility (CSR) Choices: The Moderating Role of the Legal Environment.
    Gao Q; Gao L; Long D; Wang Y
    Psychol Res Behav Manag; 2023; 16():3199-3217. PubMed ID: 37588249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEO successor origins, top management team faultline, and strategic change-empirical evidence from China.
    Ren D; Jiang H; Cheng J; Peng C; Zou Y
    Heliyon; 2023 Sep; 9(9):e19200. PubMed ID: 37662732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narcissistic CEOs, dynamic capability, and green innovation.
    Chang L; Liang R; Zhang J; Yan X; Tao H; Zhu T
    Heliyon; 2023 Aug; 9(8):e18898. PubMed ID: 37600378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chairman Narcissism and Social Responsibility Choices: The Moderating Role of Analyst Coverage.
    Gao Q; Gao L; Long D; Wang Y
    Behav Sci (Basel); 2023 Mar; 13(3):. PubMed ID: 36975270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavior Towards R&D Investment of Family Firms CEOs: The Role of Psychological Attribute.
    Zulfiqar M; Zhang R; Khan N; Chen S
    Psychol Res Behav Manag; 2021; 14():595-620. PubMed ID: 34079397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Female CEO succession and corporate social disclosure in China: unveiling the significance of ownership status and firm performance.
    Shaheen R; Luo Q; Bala H
    Environ Sci Pollut Res Int; 2023 Feb; 30(6):14223-14239. PubMed ID: 36149559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEO discretion and enterprise digital transformation.
    Wang Y; He Z
    Heliyon; 2024 Jan; 10(1):e23468. PubMed ID: 38173513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corporate financialization, financing constraints, and innovation efficiency-Empirical evidence based on listed Chinese pharmaceutical companies.
    Zhu J; Tang Y; Wei Y; Wang S; Chen Y
    Front Public Health; 2023; 11():1085148. PubMed ID: 37124778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celebrity CEOs and firm innovation investment: Evidence from Chinese-listed companies.
    Shao D; Lv K; Zhao S; Wang S
    Front Psychol; 2022; 13():978946. PubMed ID: 36478933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEOs' psychological trait and firms' adoption of blockchain technology: The role of hometown identity.
    Wang L; Xiao W; Xie S; Wei R
    Front Psychol; 2022; 13():1005249. PubMed ID: 36467173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEO turnover and corporate innovation: What can we learn from Chinese listed companies.
    Sun S; Jiang H
    Front Psychol; 2022; 13():874907. PubMed ID: 35936347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between CEO Duality and Business Firms' Performance: The Moderating Role of Firm Size and Corporate Social Responsibility.
    Mubeen R; Han D; Abbas J; Álvarez-Otero S; Sial MS
    Front Psychol; 2021; 12():669715. PubMed ID: 35035363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbon emission trading scheme and corporate labor investment efficiency: evidence from China.
    Ma J; Xiang Y; Bai X
    Environ Sci Pollut Res Int; 2023 Aug; 30(39):90830-90843. PubMed ID: 37462874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEO Regulatory Focus, Analysts' Optimism Bias, and Firm Strategic Change: Evidence From Chinese-Listed Companies.
    Huang C; Zheng W
    Front Psychol; 2022; 13():813920. PubMed ID: 35401381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.